logo
Retired railway staff can opt for Unified Pension Scheme

Retired railway staff can opt for Unified Pension Scheme

The Hindu6 hours ago

The retired railway employees under the National Pension System (NPS) now have an option to join the Unified Pension Scheme (UPS) before the end of this month.
As per the Pension Fund Regulatory and Development Authority Gazette notification dated March 25 and Railway Board Circulars (RBE No. 25/2025 and RBA No. 10/2025), the UPS has been operationalised with effect from April 1, 2025.
Those who were under the NPS and retired on or before March 31, 2025, with requisite qualifying service may opt for the UPS by submitting Form-B2 online via the CRA portal or to their divisional office.
In case of eligible deceased retirees under the NPS, their spouse/legal heir may submit the relevant forms (B3, B4, B5, or B6) to the division, said a press release.
The last date for submission is June 30. Once exercised, the option is final and irrevocable, the release stated. For assistance, contact the Welfare or Settlement Section of the respective division.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Retired railway staff can opt for Unified Pension Scheme
Retired railway staff can opt for Unified Pension Scheme

The Hindu

time6 hours ago

  • The Hindu

Retired railway staff can opt for Unified Pension Scheme

The retired railway employees under the National Pension System (NPS) now have an option to join the Unified Pension Scheme (UPS) before the end of this month. As per the Pension Fund Regulatory and Development Authority Gazette notification dated March 25 and Railway Board Circulars (RBE No. 25/2025 and RBA No. 10/2025), the UPS has been operationalised with effect from April 1, 2025. Those who were under the NPS and retired on or before March 31, 2025, with requisite qualifying service may opt for the UPS by submitting Form-B2 online via the CRA portal or to their divisional office. In case of eligible deceased retirees under the NPS, their spouse/legal heir may submit the relevant forms (B3, B4, B5, or B6) to the division, said a press release. The last date for submission is June 30. Once exercised, the option is final and irrevocable, the release stated. For assistance, contact the Welfare or Settlement Section of the respective division.

FDA observations, leadership change keep Sun Pharma stock in spotlight on Monday
FDA observations, leadership change keep Sun Pharma stock in spotlight on Monday

New Indian Express

time11 hours ago

  • New Indian Express

FDA observations, leadership change keep Sun Pharma stock in spotlight on Monday

CHENNAI: Shares of Sun Pharmaceutical Industries Ltd. are under investor scrutiny today following two significant developments announced over the weekend — the US drug regulator's audit findings at a key manufacturing facility and a major leadership transition. The US Food and Drug Administration (USFDA) issued a Form-483 with eight observations concerning manufacturing practices at Sun Pharma's Halol facility in Gujarat. While the observations do not constitute regulatory action, they point to areas requiring corrective measures to meet FDA compliance standards. Sun Pharma has acknowledged the observations and committed to addressing them promptly. The inspection, conducted between June 2 and June 13, 2025, is especially significant as the Halol plant has been under an import alert since December 2022 due to previous regulatory violations. In a parallel development, the company announced the elevation of Kirti Ganorkar to the role of Managing Director, effective September 1, 2025. Ganorkar, who has headed Sun Pharma's India business since 2019, will take over full operational responsibilities, with all functions reporting directly to him. Founder Dilip Shanghvi will continue as Executive Chairman of the Board, ensuring strategic continuity. In light of these developments, investors are expected to closely monitor the company's stock performance in the coming days. Market analysts say the resolution of USFDA concerns at Halol and the smooth execution of the leadership transition will be key to shaping investor sentiment and the company's near-term outlook.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store